Peptide · Agonist of melanocortin 4 receptor (MC4R) · developed by Rhythm
Setmelanotide is a melanocortin 4 (MC4) receptor agonist that acts on MC4 receptors in the brain, which regulate hunger, satiety and energy expenditure, to reduce food intake and promote weight loss. It has weaker activity at the MC3 and MC1 receptors. It is studied in Bardet-Biedl syndrome and Alstrom syndrome.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Apr 1, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07674290 | Phase 4 | Bardet Biedl Syndrome (BBS) | Recruiting | RYTM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Alstrom SyndromeBardet Biedl SyndromeBardet Biedl Syndrome (BBS)
Updated Nov 1, 2026. Something wrong or missing? Report it on the RYTM page.
See RYTM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RYTM catalysts and pipeline →